Crispr Therapeutics AG (CRSP)
NASDAQ · Healthcare
Crispr Therapeutics AG EBITDA 2015–2025
Crispr Therapeutics AG annual/quarterly ebitda history and growth rate from 2015 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Crispr Therapeutics AG ebitda for the quarter ending March 31, 2026 was -125.9 M, a 12.36% decrease year-over-year.
- Crispr Therapeutics AG ebitda for the twelve months ending March 31, 2026 was -464.8 M, a 15.95% increase year-over-year.
- Crispr Therapeutics AG annual ebitda for 2025 was -645.1 M, a 44.22% increase from 2024.
- Crispr Therapeutics AG annual ebitda for 2024 was -447.3 M, a 120.67% increase from 2023.
- Crispr Therapeutics AG annual ebitda for 2023 was -202.7 M, a 68.77% decrease from 2022.
- Crispr Therapeutics AG annual ebitda for 2022 was -649.0 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Crispr Therapeutics AG EBITDA — FAQ
Crispr Therapeutics AG (CRSP) ebitda over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CRSP's ebitda history?
The chart and table above show Crispr Therapeutics AG's ebitda by year and by quarter, including the growth rate.